Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 10/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.52 |
| ▸ | AHCY | P23526 | 1/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015340 | 0.83 | PRKACA (0.55) | PRKACAROCK2AHCYHSP90B1 | |
| SCHEMBL29378113 | 0.79 | ADORA2A (0.70) | ADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL13211032 | 0.78 | ENTPD2 (0.47) | ADORA3ADORA2AADORA1PRKACAROCK2 | |
| SCHEMBL14387176 | 0.73 | ADORA3 (0.40) | ADORA3ADORA2AADORA1PRKACAROCK2 | |
| SCHEMBL13211027 | 0.73 | ADORA3 (0.40) | ADORA3ADORA2AADORA1PRKACAROCK2 | |
| SCHEMBL13210961 | 0.72 | ADORA3 (0.39) | ADORA3ADORA2AADORA1PRKACAROCK2 | |
| SCHEMBL13210965 | 0.72 | ADORA3 (0.42) | ADORA3ADORA2AADORA1PRKACAROCK2 | |
| SCHEMBL13211009 | 0.72 | ENTPD2 (0.55) | ADORA3ADORA2AADORA1 | |
| SCHEMBL32660834 | 0.70 | PRKACA (1.00) | ADORA3ADORA2AADORA1PRKACAROCK2 | |
| SCHEMBL31409360 | 0.70 | PRKACA (1.00) | PRKACAROCK2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| WO-2007135195-A1 | ECTONUCLEOTIDASE INHIBITORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ADORA3 28/4885ADORA2A 32/4885ADORA1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.